Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment
Cancer Treatment and Research Communications · 2023
DOI: 10.1016/j.ctarc.2023.100757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2023. Verfasst von Paul Zarogoulidis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Department, General Clinic Euromedica, Thessaloniki, Greece; 3rd University Surgery Department, ``AHEPA`` University Hospital, Thessaloniki…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer is still diagnosed at a late disease stage and systematic therapy is necessary. Currently we have three main treatment modalities; chemotherapy, targeted with tyrosine kinase inhibitors and immune check point inhibitors. In the recent years and based on new studies we can administer combination of chemotherapy and immunotherapy, or radiotherapy and immunotherapy. Every treatment approach is based on the specific gene expression of the tumor. Tyrosine kinase inhibitors have been used for more than a decade for epidermal growth factor positive tumors, the same for anaplastic lymphoma kinase and proto-oncogene 1. Programmed death-ligand 1 expression has been found to be associated with the efficiency of immune checkpoint inhibitors. However; there are still several subpopulations in non-small cell lung cancer patients. We will comment on the group with KRAS G12C mutation and the targeted therapy with sotorasib for its efficiency and toxicity based on new studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Department, General Clinic Euromedica, Thessaloniki, Greece; 3rd University Surgery Department, ``AHEPA`` University Hospital, Thessaloniki, Greece. Electronic address: pzarog@hotmail.com.
- Oncology Department, General Hospital of Rhodes, Greece.
- Surgery Department, Democritus University of Thrace, Alexandroupolis, Greece.
- Department of Pathology, University of Cyprus, Cyprus.
- Department of Pharmacology & Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Zitieren
APA
Zarogoulidis, P., Matthaios, D., Oikonomou, P., Nikolaou, C., Charalampidis, C., & Sardeli, C. (2023). Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2023.100757
Vancouver
Zarogoulidis P, Matthaios D, Oikonomou P, Nikolaou C, Charalampidis C, Sardeli C. Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment. Cancer Treatment and Research Communications. 2023. doi:10.1016/j.ctarc.2023.100757
BibTeX
@article{Zarogoulidis2023,
author = {Zarogoulidis, Paul and Matthaios, Dimitris and Oikonomou, Panagoula and Nikolaou, Christina and Charalampidis, Charalampos and Sardeli, Chrysanthi},
title = {Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment},
journal = {Cancer Treatment and Research Communications},
year = {2023},
doi = {10.1016/j.ctarc.2023.100757}
}
EUVIMED